CRISPR Therapeutics CRSP shares are trading higher after the company and its partner Vertex Pharmaceuticals announced the EMA granted Priority Medicines designation to CTX001 for the treatment of transfusion-dependent beta thalassemia.
CTX001 is being investigated in two ongoing clinical trials as a potential one-time therapy for patients suffering from TDT and severe SCD.
CRISPR Therapeutics AG is a gene-editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics.
The stock was 7.3% higher to $135.80 at the time of writing. The stock has a 52-week high of $220.20 and a 52-week low of $46.84.
Benzinga Pro provides investors with timely and accurate explanations of why a stock is moving. Subscribe to receive real-time alerts explaining stock price movements. Click here to learn more.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
